1-methyl-3-n-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 1-methyl-3-n-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
• 英文别名: 1-methyl-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one；1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]-pyrimidin-7-one；1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one；1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
• 化学式: C₉H₁₂N₄O
• 分子量: 192.22
• InChiKey: LOVMAMBYUGCUIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidine-5-carboxylate 在 甲醇 、 lithium hydroxide 、 水 、 盐酸 作用下， 以 水 为溶剂， 反应 12.0h， 以91.5%的产率得到1-methyl-3-n-propyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
  参考文献：
  名称：

  [EN] FIBRATE COMPOUNDS HAVING PPAR AGONIST ACTIVITY
  [FR] COMPOSES DE FIBRATE POSSEDANT UNE ACTIVITE AGONISTE PPAR

  摘要：

  公开号：

  WO2006029075A3

文献信息

• [EN] PYRAZOLEPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES<br/>[FR] NOUVEAUX COMPOSÉS UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2009071706A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds that are inhibitors of PDElA, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation, and particularly, to a compound according to formula I: or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof or isotopic variants thereof, stereoisomers or tautomers thereof. The invention extends to compositions, including pharmaceutical compositions, and corresponding uses thereof, and methods of prophylaxis and treatment involving the same.

  本发明涉及一种抑制PDElA的化合物，PDElA是参与调节软骨降解、关节退化以及涉及此类降解和/或炎症的疾病的磷酸二酯酶，特别是根据式I的化合物：或其药学上可接受的盐、水合物、溶剂合物或前药，或其同位素变体、立体异构体或互变异构体。本发明还涉及包括药物组合物在内的组合物，以及其相应的用途和涉及相同的预防和治疗方法。
• Novel compounds useful for the treatment of degenerative & inflammatory diseases
  申请人：Dykes Graeme James

  公开号：US20080242661A1

  公开（公告）日：2008-10-02

  The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.

  本发明涉及一种抑制PDE1A的化合物，PDE1A是参与调节软骨降解、关节退化以及涉及此类降解和/或炎症的疾病的磷酸二酯酶。
• A facile one step synthesis of 1,6 -dihydro-7<i>H</i>-pyrazolo[4,3-<i>d</i>]-pyrimidin-7-ones
  作者：Nalla Ram Reddy、Ghanta Mahesh Reddy、Battu Saida Reddy、Padi Pratap Reddy

  DOI：10.1002/jhet.5570420502

  日期：2005.7

  A general synthetic approach to pyrazolo[4,3-d]pyrimidines is reported. Aldehydes, arylideneanilines, carboxylic acids and orthoesters are used as one-carbon units for bridging the two amino functions of 4-amino-1-alkyl-3-propylpyrazole-5-carboxamides.

  报道了吡唑并[4，3- d ]嘧啶的一般合成方法。醛，芳基苯胺，羧酸和原酸酯用作连接4-氨基-1-烷基-3-丙基吡唑-5-羧酰胺的两个氨基官能团的一个碳单元。
• Process for producing pyrimidin-4-one compound
  申请人：Nishino Shigeyoshi

  公开号：US20060270849A1

  公开（公告）日：2006-11-30

  A pyrimidin-4-one compound can be prepared in a high yield by reacting an aminoarylcarboxylic acid compound with an organic acid compound in the presence of a nitrogen atom-containing compound under relatively simple and moderate reaction conditions.

  在相对简单和温和的反应条件下，在含有氮原子的化合物的存在下，通过将氨基芳基羧酸化合物与有机酸化合物反应，可以高产率地制备一种嘧啶-4-酮化合物。
• Fibrate Compounds Having Ppar Agonist Activity
  申请人：Das Saibal Kumar

  公开号：US20080114005A1

  公开（公告）日：2008-05-15

  There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from —CH 2 —, —O—, —NH—, and —S—; Y is chosen from —O—, —NH—, and —S—; Z, which may be located in any position of substitution, is hydrogen or halogen; R 1 and R 2 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl, or R 1 and R 2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R 3 is chosen from hydrogen and C 1 -C 8 alkyl; R 4 , R 5 , and R 6 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPARα agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPARα agonist activity and a PPARα agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided.

  提供了具有PPAR激动剂活性的衍生物。这些衍生物包括化合物和/或其药学上可接受的盐；其中化合物具有公式（I），其中A具有结构（II）或（III）；X选择自—CH2—，—O—，—NH—和—S—；Y选择自—O—，—NH—和—S—；Z可以位于任何取代位置，是氢或卤素；R1和R2，可以相同也可以不同，独立地选择自氢和C1-C8烷基，或者R1和R2共同形成具有4到6个碳原子的碳环；R3选择自氢和C1-C8烷基；R4，R5和R6，可以相同也可以不同，独立地选择自氢和C1-C8烷基；n为1到6。提供了各种实施例和变体。根据其他方面，本发明还提供在哺乳动物中产生PPARα激动剂活性的方法，该方法包括向哺乳动物投与某些第一方面的衍生物的有效量，一种产生PPARα激动剂活性的方法和在哺乳动物中的PPARα激动剂活性，该方法包括向哺乳动物投与某些衍生物的有效量；以及包括第一方面的衍生物和一个或多个药学上可接受的辅料的药物组合物。提供了各种实施例和变体。